Coronavirus: Clinical Trials

8 trials for Coronavirus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Terminated 8
Phase 21Terminated 1

Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
CVnCoV Vaccine - Coronavirus, Covid19
Phase 3TerminatedCureVac1292021-04-222022-05-13
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Linagliptin 5 MG - COVID 19, Coronavirus
Phase 3TerminatedRabin Medical Center642020-10-012021-06-02
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
INOpulse, Placebo - COVID-19, Coronavirus
Phase 3TerminatedBellerophon Pulse Technologies1912020-07-122023-02-21
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
PTC299, SOC, Placebo - Pneumonia, COVID-19
Phase 2 / Phase 3TerminatedPTC Therapeutics1892020-07-092023-06-26
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?
Hydroxychloroquine, Placebo oral tablet - Pre-Exposure Prophylaxis, Coronavirus
Phase 3TerminatedMegan Landes132020-04-302021-04-29
Will Hydroxychloroquine Impede or Prevent COVID-19
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet - COVID-19, Coronavirus
Phase 3TerminatedHenry Ford Health System6242020-04-072022-06-21
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease
Hydroxychloroquine, Placebo - Coronavirus
Phase 3TerminatedUniversity Hospital, Angers2592020-04-012020-10-06
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Hydroxychloroquine, Placebo oral tablet - Corona Virus Infection, SARS-CoV Infection
Phase 3TerminatedMcGill University Health Centre/Research Institute of the McGill University Health Centre702020-03-252024-10-15

Narrower conditions

Coronavirus Infections (8)  ·  COVID-19 (7)  ·  Severe Acute Respiratory Syndrome (3)  ·  Pneumonia (2)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Respiratory Tract Diseases (1)

Broader conditions

Coronaviridae Infections (8)  ·  Infections (8)  ·  Nidovirales Infections (8)  ·  RNA Virus Infections (8)  ·  Virus Diseases (8)  ·  Lung Diseases (7)  ·  Pneumonia, Viral (7)  ·  Respiratory Tract Infections (7)  ·  Respiratory Tract Diseases (6)  ·  Pneumonia (5)  ·  Nutritional and Metabolic Diseases (1)

Interventions

Hydroxychloroquine (3)  ·  CVnCoV COVID-19 vaccine (1)  ·  Linagliptin (1)  ·  emvododstat (1)

Sponsors

Bellerophon Pulse Technologies (1)  ·  CureVac (1)  ·  Henry Ford Health System (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)  ·  Megan Landes (1)  ·  PTC Therapeutics (1)  ·  Rabin Medical Center (1)  ·  University Hospital, Angers (1)

Countries

United States (4)  ·  Belgium (2)  ·  Canada (2)  ·  France (2)  ·  Australia (1)  ·  Brazil (1)  ·  Colombia (1)  ·  Israel (1)  ·  Mexico (1)  ·  Monaco (1)  ·  Poland (1)  ·  Portugal (1)  ·  South Africa (1)  ·  Spain (1)

Top investigators

Ashika Ahmed, MD (1)  ·  Dee Dee Wang, MD (1)  ·  Kevin Kain, MD (1)  ·  Megan Landes, MD (1)  ·  Quintus Ngumah, OD, PhD (1)  ·  Todd C Lee, MD MPH FIDSA (1)  ·  William W O'Neill, MD (1)

Results publications

PMID 32492293, PMID 32673060, PMID 33813110, PMID 35002970